Cubist Sets Sights On European Antibiotics Market With Zurich Move: A Conversation With Patrick Vink
Cubist recently has seen its key antibiotic Cubicin become a blockbuster in the U.S. It is determined to take this success, backed by a flourishing pipeline, to answer Europe's call for products to fight antimicrobial resistance.
You may also be interested in...
President and Chief Operating Officer Robert Perez will succeed Michael Bonney as CEO effective Jan. 1, taking over the top leadership spot at a time when the specialty pharma is in the midst of a transformation into a multi-asset company.
Incentives added under GAIN may not be “the end-all or be-all” but they are “a good start,” Cubist’s Steven Gilman says. Five years of additional exclusivity can mean a lot to smaller companies, and he thinks the clinical benefit of new drugs can support prices matching that value.
Governments are taking on different initiatives to solve the problem of developing products to address worries about drug-resistant bacteria. The EU is helping to fund trials, while the U.S. is offer extended exclusivity.